Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Girard

Showing results (231-240 of 396) with videos related to

Pageof 40
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 2, 2024
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG studyThierry J Molina, Anja C Roden, Malgorzata Szolkowska, et al.
Cancers|July 13, 2024
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-AnalysisNicolas Girard, Mariam Besada, Basia Rogula, et al.
Translational Lung Cancer Research|October 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinomaGary Birsen, Valérie Gounant, Nicolas Girard, et al.
Journal of Medicinal Chemistry|September 21, 2023
Robust Strategy for Hit-to-Lead Discovery: NMR for SARSacha T Larda, Yann Ayotte, Maria M Denk, et al.
Cancers|February 20, 2025
Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. <i>Cancers</i> 2024, <i>16</i>, 2492Nicolas Girard, Mariam Besada, Basia Rogula, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Science Immunology|January 30, 2021
Contribution of resident and circulating precursors to tumor-infiltrating CD8<sup>+</sup> T cell populations in lung cancerPaul Gueguen, Christina Metoikidou, Thomas Dupic, et al.
Pathology, Research and Practice|November 5, 2015
Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypesVincent Thomas de Montpréville, Pauline Quilhot, Lara Chalabreysse, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, et al.
Nature Communications|January 12, 2025
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancerNicolas Captier, Marvin Lerousseau, Fanny Orlhac, et al.
Pageof 40

Showing results (231-240 of 396) with videos related to

Sort By:
Pageof 40
Lung Cancer (Amsterdam, Netherlands)|February 2, 2024
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG studyThierry J Molina, Anja C Roden, Malgorzata Szolkowska, et al.
Cancers|July 13, 2024
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-AnalysisNicolas Girard, Mariam Besada, Basia Rogula, et al.
Translational Lung Cancer Research|October 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinomaGary Birsen, Valérie Gounant, Nicolas Girard, et al.
Journal of Medicinal Chemistry|September 21, 2023
Robust Strategy for Hit-to-Lead Discovery: NMR for SARSacha T Larda, Yann Ayotte, Maria M Denk, et al.
Cancers|February 20, 2025
Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. <i>Cancers</i> 2024, <i>16</i>, 2492Nicolas Girard, Mariam Besada, Basia Rogula, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Science Immunology|January 30, 2021
Contribution of resident and circulating precursors to tumor-infiltrating CD8<sup>+</sup> T cell populations in lung cancerPaul Gueguen, Christina Metoikidou, Thomas Dupic, et al.
Pathology, Research and Practice|November 5, 2015
Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypesVincent Thomas de Montpréville, Pauline Quilhot, Lara Chalabreysse, et al.
Lung Cancer (Amsterdam, Netherlands)|October 14, 2021
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, et al.
Nature Communications|January 12, 2025
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancerNicolas Captier, Marvin Lerousseau, Fanny Orlhac, et al.
Pageof 40